Literature DB >> 26735148

Barriers to Cervical Cancer Screening in Geneva (DEPIST Study).

Rosa R Catarino1, Pierre P Vassilakos, Isabelle I Royannez-Drevard, Cécile C Guillot, Stéphanie S Alzuphar, Aurore A Fehlmann, Ulrike U Meyer-Hamme, Patrick P Petignat.   

Abstract

OBJECTIVES: Cervical screening is only efficient if a large part of eligible women participate. Our aim was to identify sociodemographic barriers to cervical screening and consider self-reported reasons to postpone screening.
METHODS: Between September 2011 and June 2015, a questionnaire addressing reasons for nonparticipation in cervical screening was completed by 556 women who had not undergone a Pap test in the preceding 3 years. Pearson χ test was used to analyze differences between subgroups. Logistic regression was used to explore the association between sociodemographic characteristics and reasons for nonparticipation.
RESULTS: The main reasons for nonparticipation in cervical cancer screening were practical barriers, such as lack of time and the cost of screening. These barriers were more likely to be reported by working women, women who were not sexually active, and those without health insurance. Younger women, non-European women living in Switzerland, and childless women were more likely to have never participated in a screening program before (adjusted odds ratio [aOR], 3.15; 95% CI, 1.41-6.98; aOR, 2.76; 95% CI, 1.48-5.16; aOR, 1.74; 95% CI, 1.03-2.99, respectively).
CONCLUSIONS: Practical considerations seem to play a more important role in screening participation than emotional reasons and other beliefs. Particular attention should be paid to immigrant communities, where women seem more likely to skip cervical screening.

Entities:  

Mesh:

Year:  2016        PMID: 26735148     DOI: 10.1097/LGT.0000000000000173

Source DB:  PubMed          Journal:  J Low Genit Tract Dis        ISSN: 1089-2591            Impact factor:   1.925


  7 in total

1.  Reactions of women underscreened for cervical cancer who received unsolicited human papillomavirus self-sampling kits.

Authors:  Colin Malone; Jasmin A Tiro; Diana Sm Buist; Tara Beatty; John Lin; Kilian Kimbel; Hongyuan Gao; Chris Thayer; Diana L Miglioretti; Rachel L Winer
Journal:  J Med Screen       Date:  2019-11-20       Impact factor: 2.136

2.  Cost-effectiveness studies of HPV self-sampling: A systematic review.

Authors:  Colin Malone; Ruanne V Barnabas; Diana S M Buist; Jasmin A Tiro; Rachel L Winer
Journal:  Prev Med       Date:  2020-01-03       Impact factor: 4.018

3.  Self-sampling to improve cervical cancer screening coverage in Switzerland: a randomised controlled trial.

Authors:  Manuela Viviano; Rosa Catarino; Emilien Jeannot; Michel Boulvain; Manuela Undurraga Malinverno; Pierre Vassilakos; Patrick Petignat
Journal:  Br J Cancer       Date:  2017-04-20       Impact factor: 7.640

4.  Impact of family physicians on cervical cancer screening: cross-sectional questionnaire-based survey in a region of southern Poland.

Authors:  Katarzyna Nessler; Sze Kay Florence Chan; Francis Ball; Monika Storman; Michal Chwalek; Anna Krztoń-Królewiecka; Elżbieta Kryj-Radziszewska; Adam Windak
Journal:  BMJ Open       Date:  2019-08-30       Impact factor: 2.692

5.  HPV self-sampling in the follow-up of women after treatment of cervical intra-epithelial neoplasia: A prospective study in a high-income country.

Authors:  Manuela Viviano; Pierre Vassilakos; Ulrike Meyer-Hamme; Lorraine Grangier; Shahzia Lambat Emery; Manuela Undurraga Malinverno; Patrick Petignat
Journal:  Prev Med Rep       Date:  2021-09-20

6.  A population survey on beliefs around cervical cancer screening: determining the barriers and facilitators associated with attendance.

Authors:  Gaby Judah; Faisal Dilib; Ara Darzi; Sarah Huf
Journal:  BMC Cancer       Date:  2022-05-09       Impact factor: 4.638

7.  Harms and benefits of cervical cancer screening among non-attenders in Switzerland: The transition towards HPV-based screening.

Authors:  Rosa Catarino; Pierre Vassilakos; Patrick Petignat; Christophe Combescure
Journal:  Prev Med Rep       Date:  2022-07-30
  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.